Frequency of Pulmonary Hypertension in Post-Tuberculosis Patients: A Cross-Sectional Analysis
Keywords:
Tuberculosis, Pulmonary Hypertension, FrequencyAbstract
Background: Tuberculosis (TB) is a chronic infectious disease caused by airborne transmission of aerosolized droplets of Mycobacterium tuberculosis. TB is one of the top ten causes of death and the leading cause from a single infectious agent, causing an estimated 1.2 million deaths annually. Even with successful treatment patients with TB mostly suffer from long-term pulmonary complications. Objective: To determine the Frequency of Pulmonary Hypertension (PH) in post TB patients. Methodology: This cross-sectional study was carried out at Pulmonology Ward, Ayub Teaching Hospital, Abbottabad over six months from February 4th, 2022 to August 3rd, 2022. A total of 108 patients were included in the study using consecutive sampling technique. The PH patients included those patients who had mean pulmonary arterial pressure (PAPm) ≥ 25 mmHg at rest estimated by echocardiography. Both male and female patients with age between 16 to 80 years having past history of TB were included. Results: Mean age of Post TB patients was 52.1(±7.2) years. Among Post TB patients 46.3% were males and 53.7% were female patients. The frequency of PH in post TB patients was 44.4% (p<0.03). The Post TB PH difference in different age groups was significant (p=0.03) but difference in both genders was not significant in patients (p=0.221). Conclusion. In conclusion, Pulmonary Hypertension (PH) is highly prevalent in post-TB patients, with age being a significant factor. This underscores the importance of monitoring PH in patients recovering from TB, especially in older age groups.References
Grace AG, Mittal A, Jain S, Tripathy JP, Satyanarayana S, Tharyan P, et al. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Cochrane Database Syst Rev 2019;12:CD012918.
Bagcchi S. WHO's global tuberculosis report 2022. Lancet Microbe. 2023;4(1) DOI: 10.1016/s2666-5247(22)00359-7.
World Health Organization (WHO). Global Tuberculosis Report 2021. Geneva, WHO, 2021. Available for URL: www.who.int/publications/i/item/9789240037021.
Kalla IS, Miri A, Seedat F. Occult pulmonary arterial hypertension in patients with previous pulmonary tuberculosis. Afr J Thoracic Crit Care Med 2020;26:133-137.
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwaâ€Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4:306–22.
Wijeratne TD, Lajkosz K, Brogly SB, Lougheed M, Jiang J, Housin A, et al. Increasing incidence and prevalence of World Health Organization Groups 1 to 4 pulmonary hypertension: a populationâ€based cohort study in Ontario, Canada. Circ Cardiovasc Qual Outcomes. 2018;11:1–13.
Strange G, Playford D, Stewart S, Deague JA, Nelson H, Kent A, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012;98:1805–11.
Rich S, Haworth SG, Hassoun PM, Yacoub MH. Pulmonary hypertension: the unaddressed global health burden. Lancet Respir Med. 2018;6:577–579.
Morrell N. Heart and lung disease review series. Chron Respir Dis. 2009;6:175.
Chen Y, Liu C, Lu W, Li M, Hadadi C, Wang EW, et al. Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: a retrospective study. J Thorac Dis. 2016;8:350–358.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913. DOI: 10.1183/13993003.01913-2018.
Dodd PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, Seddon JA. Quantifying the global number of tuberculosis survivors: a modelling study. Lancet Infect Dis. 2021;3099:1–9.
Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Longâ€term allâ€cause mortality in people treated for tuberculosis: a systematic review and metaâ€analysis. Lancet Infect Dis. 2019;19:1129–37.
Datta S, Evans CA. Healthy survival after tuberculosis. Lancet Infect Dis. 2019;19:1045–47.
Allwood B, van der Zalm M, Makanda G, Mortimer K, Andre FSA, Uzochukwu E, et al. The long shadow postâ€tuberculosis. Lancet Infect Dis. 2019;19:1170–71.
Bhattacharyya P, Saha D, Bhattacherjee P, Das S, Bhattacharyya P, Dey R. Tuberculosis associated pulmonary hypertension: the revelation of a clinical observation. Lung India. 2016;33:135–139
Stewart S, Mocumbi AO, Carrington MJ, Pretorius S, Burton R, Sliwa K. A notâ€soâ€rare form of heart failure in urban black Africans: pathways to right heart failure in the Heart of Soweto Study cohort. Eur J Heart Fail. 2011;13:1070–77.
Butrous G. Pulmonary hypertension: From an orphan disease to a global epidemic. Glob Cardiol Sci Pract 2020;2020:e202005.
van Heerden JK, Louw EH, Thienemann F, Engel ME, Allwood BW. The prevalence of pulmonary hypertension in post-tuberculosis and active tuberculosis populations: a systematic review and meta-analysis. Eur Respir Rev. 2024;33(171).
Saydain G, Awan A, Manickam P, Kleinow P, Badr S. Pulmonary hypertension an independent risk factor for death in intensive care unit: correlation of hemodynamic factors with mortality. Clin Med Insights Circ Respir Pulm Med. 2015:CCRPM-S22199.
Jafri S, Jawad N, Ahmed N, Saifullah N, Siddiqui IA. Post Pulmonary Tuberculosis: The Right Heart Story. Biol Med 2020;12:466.
Kapoor SC. Pathogenesis of cor pulmonale in pulmonary tuberculosis. Ind J Tuberc. 1986;33:167–70.
McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(Suppl 1):14S–34S.
Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 1985;6(2):359-65. DOI: 10.1016/s0735-1097(85)80172-8.
Rizvi N, Shah RH, Inayat N, Hussain N. Differences in clinical presentation of pulmonary tuberculosis in association with age. J Pak Med Assoc. 2003;53(8).
Jo YS, Park JH, Lee JK, Heo EY, Chung HS, Kim DK. Risk factors for pulmonary arterial hypertension in patients with tuberculosis-destroyed lungs and their clinical characteristics compared with patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017:2433-43.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Chest Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
